Artiva Biotherapeutics, Inc. (ARTV) Stock

Artiva Biotherapeutics, Inc. (ARTV) is a Healthcare stock trading at $9.79 (as of 2026-06-18), with a market capitalization of $172.28M and a trailing P/E of -2.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company developing off-the-shelf natural killer (NK) cell therapies and allogeneic CAR-NK product candidates. Its programs include AB-101 for autoimmune diseases and cancers and additional candidates including AB-201 and AB-205, targeting conditions such as lupus nephritis, rheumatoid arthritis, and certain lymphomas.

Valuation — source: SEC EDGAR (first-party)
Price	$9.79
Market Cap	$172.28M
P/E Ratio	-2.4
EV / EBITDA	-2.1
Price / Book	2.40
DCF Value (model)	$-53.55
DCF Upside vs Price	-647.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-99.1%
Current Ratio	8.16
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	-41.0%
FCF Growth (YoY)	42.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	2.04 (grey)

Valuation vs Sector & Industry
Stock P/E	-2.4
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-111.5%
vs Industry	-114.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RA CAPITAL MANAGEMENT, L.P. ($63.46M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Fred Aslan
Employees	96
Country	US
IPO Date	2024-07-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.